Five Prime Therapeutics (FPRX) Commences Cabiralizumab Combo Phase 1b in CSF1R
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- European stocks gain as dollar eases, oil prices fall
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Dollar rally stalls after rare FX warning from finance chiefs
- Oil stabilises after sharp drop on demand concerns, easing of Middle East tension
- Netflix's subscribers, TSMC, Tesla upside - what's moving markets
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Crude Inventory Rose 2.7 Million Barrels Last Week, Says EIA
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
Five Prime Therapeutics Advances into Phase 1b Portion of Trial Evaluating the Immunotherapy Combination of Cabiralizumab (FPA008) and OPDIVO (nivolumab) in Multiple Tumor Types
October 4, 2016 9:00 AM EDTPhase 1a/1b trial on track to enroll approximately 280 patientsPhase 1b portion of the trial will assess safety, tolerability and initial efficacy in multiple tumor types
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq: FPRX) a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that it has initiated the Phase 1b portion of the clinical trial evaluating the immunotherapy combination of cabiralizumab (FPA008), Five Prime's investigational monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R), with OPDIVO®... More
